Physiomics PLC Virtual Tumour Developments Presentation at AACR
06 April 2016 - 7:15PM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
06 April 2016
Physiomics plc
("Physiomics") or ("the Company")
Physiomics to give an oral presentation on new developments of
the Virtual Tumour platform in drug resistance at Annual Meeting
for American Association for Cancer Research ("AACR")
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology
company, is pleased to announce that it is participating in the
AACR Annual Meeting 2016, taking place at the Ernest N. Morial
Convention Center, New Orleans, Louisiana on 16-20 April 2016. Dr
Eric Fernandez will present on the application of the Virtual
Tumour ("VT") platform to predict the emergence of resistance.
Drug resistance is a major cause of treatment failure in cancer,
and understanding and overcoming mechanisms of resistance is a key
challenge in advancing cancer therapy. Given the significance of
cancer drug resistance, and the form that future cancer therapy is
likely to take, Physiomics is actively engaged in developing
personalized medicine solutions. As a first step, we have
incorporated chemotherapeutic resistance into our Virtual Tumour
platform. This VT extension captures the fundamental mechanism by
which resistance arises. Through a case study, we demonstrate that
the extended VT can be applied to model the emergence of resistance
in patient-derived xenografts. Furthermore, we show that the VT can
be used to identify and optimize therapeutic strategies for
delaying the emergence of drug resistance. Such tool could help at
the patient level to improve a key clinical metric the "time to
relapse", i.e. how long it takes for a patient to become resistant
to a given treatment.
The abstract ("Modeling the emergence of resistance to
chemotherapeutics with virtual tumor ", No 852) will be presented
in the "Novel and Integrative Analyses of Cancer Genome Data",
Minisymposium session, scheduled 4:15 PM-6:15 PM, 17 April
2016.
More information about the conference may be found at:
http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=63&DetailItemID=363#.VvqCVMLrucx
Dr Christophe Chassagnole, COO of Physiomics, commented:
"Our enhanced Virtual Tumour capability represents the first
step towards a ground-breaking tool for developing personalized
treatment, which is set to revolutionize cancer therapy in the near
future, especially for patients with resistant disease."
Enquiries:
Physiomics plc
Dr Mark Chadwick, CEO
+44 (0)1865 784 980
WH Ireland Limited (broker/nomad)
Katy Mitchell
+44 (0)161 832 2174
About Physiomics plc
Physiomics (AIM:PYC) is a computational systems biology services
company applying simulations of cell behaviour to drug development
to reduce the high attrition rates of clinical trials. 80-90 per
cent of all clinical drug candidates fail to reach the market and
estimates show that an overall ten per cent improvement in success
rates could reduce the cost of one drug's development by as much as
$242 million, from the current estimate of around $800 million(1)
.
Physiomics develops computational systems biology models to
predict and understand cancer drug efficacy from pre-clinical
research to clinical development. Physiomics has created detailed
mathematical models incorporating the most important molecular
events taking place during the human cell cycle and apoptosis
processes. The company's SystemCell(R) technology enables the
simulation of populations of "virtual cells". The company has also
developed a "Virtual Tumour" model to simulate the effect of
anti-cancer drugs on tumour growth. The models are used to optimise
compound design and to design drug schedules and combination
therapies.
Physiomics, based in Oxford, UK, was founded in 2001, and
floated on AIM in 2004. For further information, please visit
www.physiomics-plc.com
SystemCell(R) is a registered trademark of Physiomics plc
(1) Tufts Centre Impact Report 2002
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAAKADDCBKKQQK
(END) Dow Jones Newswires
April 06, 2016 05:15 ET (09:15 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024